Navigation Links
What does the public really know about HPV?

Human papillomaviruses (HPV) are the most common sexually transmitted infections in the United States, and certain "high risk" types have been shown to cause cervical cancer. Despite recent advances in the detection and prevention of HPV, the link between the virus and cervical cancer is not well known to the public. In June 2006, the Food and Drug Administration (FDA) approved the first vaccine to prevent infection of two high risk types of HPV, and two types that cause genital warts. The Advisory Committee on Immunization Practices (ACIP) recommended it for females 9 to 26 years of age.

Two studies presented today at the American Association for Cancer Research's Frontiers in Cancer Prevention Research meeting in Boston assess the public's understanding of HPV and whether discussion of the vaccine by the media and public has influenced the decision to vaccinate among women at risk.

What Do U.S. Women Know About Human Papillomavirus (HPV) and Cervical Cancer?

Many women with HPV show no symptoms of the virus, and infections often clear without need for treatment. Because of this, many women do not have the opportunity to speak with their physicians about HPV and therefore may not learn that some HPV infections are persistent and can develop into cervical cancer.

The National Cancer Institute (NCI) created the Health Information National Trends Survey (HINTS) to monitor health communications about cancer. In 2005, one high-priority research aim was to assess, for the first time, the awareness and knowledge of HPV in a nationally representative sample of women.

To identify factors associated with U.S. women's awareness of HPV and its link to cervical cancer, researchers from NCI analyzed cross-sectional data collected from more than 3,000

women ages 18 to 75 who responded to HINTS. Researchers found that:

  • Only 40 percent had ever heard about HPV;
  • Among them, less than ha lf were aware of the virus' connection to cervical cancer;
  • 64 percent knew that HPV could be sexually transmitted, and 79 percent knew it could cause abnormal Pap smears.

The public needs education about HPV and cervical cancer in order to make appropriate, evidence-based health care choices among existing prevention strategies, including the Pap test, HPV DNA test, and HPV vaccine, researchers concluded.

"Individuals are constantly being presented with new health care research that updates previous knowledge, might conflict with prior knowledge, or provides entirely new options for diagnosis and treatment," said Jasmin A. Tiro, Ph.D., MPH, in the Division of Cancer Control and Population Sciences, NCI, Bethesda, Md. "With limited awareness about HPV among women in this country, there is a need for clear, consistent information about HPV transmission, prevention, detection and the link to cervical cancer. We expect that media coverage over the past year and direct-to-consumer marketing efforts by the makers of the HPV DNA test and the HPV vaccine will increase awareness, and NCI is conducting studies to monitor this possible increase. We plan to track the diffusion of knowledge to make sure that all women have accurate knowledge about HPV and how to prevent cervical cancer."

The Effects of Information Framing on Intentions to Vaccinate Against HPV

The success of the HPV vaccine depends largely on the public's willingness to accept vaccination. Because of the potentially controversial nature of the vaccine, researchers at the University of Pennsylvania's EPIC Center of Excellence in Cancer Communication Research assessed how its portrayal in the media would affect attitudes toward vaccination among women.

The study was a part of the Annenberg National Health Communication Survey, a monthly barometer of the public's health communication practices and needs. The survey is jointly funded by the Nat ional Cancer Institute, the Annenberg School for Communication and the Sunnylands Trust at Annenberg. It was fielded in June, 2006, roughly coinciding with FDA approval of the vaccine.

A nationally representative sample of U.S. adults over 18 was randomly assigned to read one of three paragraphs about the vaccine, each emphasizing a different point of view: the vaccine protects against cervical cancer; the vaccine protects against cervical cancer and sexually transmitted infections; or, the vaccine protects against cervical cancer, sexually transmitted infections and may or may not lead to increased sexual promiscuity among those vaccinated. The survey was then given to gauge intentions toward vaccination. It was completed by 635 adults, 49 percent of whom were women.

Researchers found:

  • More than half of respondents (56 percent) had heard of HPV and reported that they had seen or heard news or ads about HPV in the past week;
  • Although 42 percent of respondents had heard about a vaccine for HPV, 80 percent indicated never having talked to a health care provider about the virus.

How the vaccine was presented greatly affected women's intentions to vaccinate. When women read that the vaccine protects only against cervical cancer, 63 percent indicated they were "very likely" or "somewhat likely" to get vaccinated, compared to 43 percent of women who read that the vaccine protects against cervical cancer and a sexually transmitted infection.

"Despite high levels of exposure to and awareness of the newly approved HPV vaccine, intentions to vaccinate are mixed," said Amy Leader, MPH, Research Director, EPIC Center of Excellence in Cancer Communication Research. "Trends indicate that intentions are highest when the vaccine is framed to solely prevent cervical cancer and lowest when the vaccine is framed to prevent both cervical cancer and a sexually transmitted infection, or STI, indicating that people may feel the need for an STI vaccine is unnecessary."

Participants were also asked about their intentions to vaccinate if they had to pay for the vaccine or if the vaccine were provided at little or no cost. Although the majority reported having some form of health insurance coverage, intentions to vaccinate one's self or a daughter were substantially higher when the vaccine was available at little or no cost. For example, 54 percent of parents indicated that they were "very likely" or "somewhat likely" to want the vaccine for their daughter if it were provided at little or no cost, compared to 38 percent of parents who would consider the vaccine for their daughter if it would cost their family.

Source:American Association for Cancer Research

Related biology news :

1. New push for public health, AIDS spending at African Union summit
2. Wiley announces publication of Databasing the Brain
3. BioMed Central welcomes the new National Institutes of Health public access policy
4. Not-for-profit publishers call NIH public access rule a missed opportunity
5. CoPub Mapper: mining MEDLINE based on search term co-publication
6. DOE JGI launches IMG public online microbial genome data clearinghouse
7. Understanding biases in epidemic models important when making public health predictions
8. Does manganese inhaled from the shower represent a public health threat?
9. Center releases new public survey on stem cells
10. HIV-infected adults in Botswana respond positively to ARV therapy public treatment program
11. Scientists fetch useful information from dog genome publications

Post Your Comments:

(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
(Date:11/24/2015)... Nov. 24, 2015  Twist Bioscience, a company ... Leproust, Ph.D., Twist Bioscience chief executive officer, will ... on December 1, 2015 at 3:10 p.m. Eastern ... City. --> --> ... Twist Bioscience is on Twitter. Sign up to ...
(Date:11/24/2015)... - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" ... , President and Chief Executive Officer of ProMetic, will be ... th Annual Healthcare Conference to be held at the ... st , at 8.50am (ET) and ProMetic,s management team ... presentation will be available live via a webcast accessible at ...
Breaking Biology Technology: